AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$CORT

Vieira Roberto Wandenkolk sold $30K of CORT

Vieira Roberto Wandenkolk (President, Oncology) sold 296 shares of CORCEPT THERAPEUTICS INC (CORT) at $100.82 on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Vieira Roberto Wandenkolk
Published Sep 18, 2026, 11:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 11:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
high confidence
Mentioned
$CORT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The disclosed sale is modest and pre-arranged, suggesting no immediate market impact.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data could change relevance of insider activity.

Relevance 2/10Novelty 3/10Timing: filed Sep 18 2026

Background

Form 4 filing reports insider transactions required by SEC; provides transparency on insider holdings.

Company-level read

Ticker impact

$CORTNeutralHigh confidence
Context

Officer sold 296 shares for $29,842.72 via 10b5-1 plan on Sep 16, 2026.

Expected impact

No material impact expected.

Evidence & confidence

Sale size is small relative to float and disclosed via pre-arranged plan.

Market effects

Sector

None; isolated insider transaction.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor future filings.

Key entities

  • Company
    Corcept Therapeutics Inc.

    Biopharma company developing cortisol receptor antagonists.

  • Insider
    Vieira Roberto Wandenkolk

    President, Oncology at Corcept Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CORT insider trading history →

Related articles

OCT 26
$CORTHighAI 8/10

Why is Corcept Therapeutics stock rallying today?

Corcept Therapeutics (CORT) stock rose 3.7% in pre-market trading after reporting positive Phase 2 BELLA trial results for Lifyorli in combination with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer. The study showed improved median progression-free survival (7.2 months) and objective response rate (59%) compared to the two-drug combination. The stock had previously declined 29.6% due to competitive concerns from Genmab's trial results.

investing.com2 min
OCT 23
$CORTHighAI 8/10

Corcept Therapeutics (CORT) Shares Drop 20% on Genmab's Phase 3

Corcept Therapeutics (CORT) shares dropped 20% to $85.86 after Genmab's phase 3 trial for a competing ovarian cancer drug succeeded, raising concerns about market competition. CORT's GF Value™ suggests it is 11.2% overvalued, while its GF Score™ is 85/100, indicating strong financial health. Insiders have sold $101.5M in shares over the past year, signaling caution.

gurufocus.com3 min
OCT 23
$CORTHighAI 8/10

Why is Corcept Therapeutics stock tumbling today?

Corcept Therapeutics (CORT) shares fell 12.9% after Genmab's rival drug showed positive results in a Phase 3 trial for platinum-resistant ovarian cancer, directly competing with Corcept's Lifyorli. The decline was exacerbated by prior downgrades and market headwinds, with shares dropping from $106.05 to a low of $90.99 before partially recovering to $93.68.

investing.com2 min
SEP 22
$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min